Show Notes:
In this episode of Docs Who Lift, the Nadolsky brothers welcome back Dr. Sean Wharton, clinical trialist and one of the leading researchers behind the next generation of oral GLP-1 medications. Together, they break down:

The OASIS-4 trial results on 25mg oral semaglutide and how it stacks up to injectable Wegovy

How orforglipron, Eli Lilly’s new small-molecule GLP-1, differs from peptide-based drugs

Why these new therapies could make weight management more accessible and affordable

The fascinating pharmacology behind “snack molecules” and small-molecule receptor agonists

Common misconceptions about bioavailability, dosing, and side effects

The potential role of oral GLP-1s for patients with mild obesity or cardiometabolic disease

Whether you’re a clinician, researcher, or patient curious about the future of obesity medicine, this conversation offers a clear look at how science is shifting toward needle-free solutions.

Oasis 1 Trial Link

Oasis 4 Trial Link

Attain 1 Trial Link

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Eric German (Entertainment Lawyer)